← Leaderboards
Bobby Reddy
Prenosis, Inc.
$8,396,645
Attributed
$8,396,645
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3.1M · FY2017–25$5M$3.8M$2.5M$1.3M$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,246,645 · 4
CDC$150,000 · 1
By mechanism
R44$8,246,645 · 4
R43$150,000 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Immune Response”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$143,577,666
- Kevin Urdahl · Seattle Children'S Hospital$85,664,942
- Ted Ross · University Of Georgia$74,507,826
- Yunda Huang · Fred Hutchinson Cancer Center$72,098,149
- Sarah Fortune · Harvard School Of Public Health$51,119,645
- Scott Hensley · University Of Pennsylvania$49,058,212
Research focus
Immune ResponseSamplingData SetClinical DataInfectionBiobankProgramsHospitalsPrincipal InvestigatorMeasurementSepsisBiological MarkersHeterogeneityProtein BiomarkersAwardSeriesPlasmaMapsMachine LearningClinical Decision SupportComputerized Medical RecordClinical TrialsHourSite
Grant awards (9)
Clinical Validation of a Point-of-Care Precision Medicine Endotyping Platform$700,000
R44 · FY2025 · GM · contact PI
Use of Time Series Biomarker and Clinical Data to Construct a Time Trajectory Host Response Map$1,272,176
R44 · FY2024 · GM · contact PI
Combined Biomarker and EMR Data for Heterogeneous Treatment Effects and Surrogate Endpoints in Sepsis$1,161,624
R44 · FY2024 · GM · contact PI
Clinical Validation of a Point-of-Care Precision Medicine Endotyping Platform$700,000
R44 · FY2024 · GM · contact PI
Use of Time Series Biomarker and Clinical Data to Construct a Time Trajectory Host Response Map$1,272,176
R44 · FY2023 · GM · contact PI
Combined Biomarker and EMR Data for Heterogeneous Treatment Effects and Surrogate Endpoints in Sepsis$1,161,624
R44 · FY2023 · GM · contact PI
Collaborative Platform for Developing Sepsis Products by Leveraging Sepsis Endotypes Developed Using a Unified Biomarker-Clinical Dataset$989,522
R44 · FY2021 · GM · contact PI
Collaborative Platform for Developing Sepsis Products by Leveraging Sepsis Endotypes Developed Using a Unified Biomarker-Clinical Dataset$989,523
R44 · FY2020 · GM · contact PI
Point of Care Device for Reducing Overuse of Antibiotics in Potentially Septic Hospital Populations$150,000
R43 · FY2017 · CK · contact PI